Core Viewpoint - The recent collaboration between YuanDa Pharmaceutical and YouEr Pharmaceutical Technology marks a significant advancement in the treatment of severe allergic reactions, with the introduction of the first non-injection epinephrine nasal spray, Neffy®, in China [1][4]. Group 1: Product Collaboration and Market Entry - YuanDa Pharmaceutical has secured exclusive commercialization rights for Neffy® in mainland China and non-exclusive rights in Hong Kong, covering both 2mg and 1mg formulations [1]. - The product has been submitted for regulatory approval in China, with the application accepted by the National Medical Products Administration [1][4]. Group 2: Medical Significance and Urgency - I-type allergic reactions, particularly severe ones, can escalate rapidly, necessitating immediate medical intervention to prevent fatalities [2]. - Epinephrine is the recommended first-line treatment for severe allergic reactions, and early administration has been shown to significantly reduce hospitalization and mortality rates [2]. Group 3: Innovation in Delivery Method - Neffy® represents a breakthrough as the first FDA-approved non-injection treatment for I-type allergic reactions, utilizing a nasal spray delivery method that enhances ease of use and accessibility [3][4]. - The product's design allows for quick administration by patients or bystanders, addressing the limitations of traditional injection methods [3]. Group 4: Market Potential and Financial Projections - Neffy® has already achieved significant sales in the U.S., with revenue reaching $12.8 million in Q2 2025, reflecting a growth of approximately 180% [4]. - Global revenue projections for Neffy® are expected to reach $54 million in 2025, with potential to approach $500 million by 2028 [4].
远大医药斩获全球首款治疗I型过敏肾上腺素鼻喷雾剂